Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05469802 Withdrawn - Healthy Volunteers Clinical Trials

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Start date: January 2, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to describe the side effects and immune response of a candidate vaccine that might protect against Zika. The vaccine called PIZV (purified inactivated Zika virus vaccine) is given by injection in two doses that are 28 days apart in healthy adults. Participants will receive PIZV or placebo and will be followed for 7 days after each dose and up to 6 months after dose 2.

NCT ID: NCT05406219 Withdrawn - Healthy Volunteers Clinical Trials

A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function

Start date: May 15, 2023
Phase: Phase 1
Study type: Interventional

Researchers are looking for a better way to treat people who have inflammatory conditions. Inflammatory conditions may result from an increased activation of the body's natural defenses (the immune system) and are characterized by swelling, redness, heat, and pain. The study treatment BAY2395840 is under development for use in inflammatory conditions. It works by blocking a protein, the B1 receptor, whose activation is involved in inflammatory responses. The main purpose of this study is to learn how a single dose of BAY2395840 moves into, through and out of the body in participants with a moderate reduction of kidney function compared to matched participants with normal kidney function. To answer this, the researchers will compare: - the (average) total level of BAY2395840 in the blood (also known as AUC), and - the (average) highest level of BAY2395840 in the blood (also known as Cmax) between the two groups of participants. The participants do not benefit from this study. However, the study will provide information on how to use BAY2395840 in later studies in people with inflammatory conditions. As some people with these conditions may also have kidney problems, this study is done in participants with moderate reduction of kidney function to characterize the use of BAY2395840 in this patient group. All participants will take a single dose of BAY2395840 as tablets. Each participant will be in the study for up to 5 weeks. They will stay in-house for 4 days, including one treatment day. In addition, one visit before and one visit after the in-house phase to the study site is planned.

NCT ID: NCT05387668 Withdrawn - Healthy Volunteers Clinical Trials

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

Start date: February 17, 2022
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the influence of ethnic factors on the safety, tolerability, and pharmacokinetics (PK) of BGB-23339 after multiple dosing under fasting condition in healthy Japanese and Caucasian participants.

NCT ID: NCT05309902 Withdrawn - Healthy Volunteers Clinical Trials

A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval

Start date: October 11, 2022
Phase: Phase 1
Study type: Interventional

The main aim is to see if soticlestat has any effect in the heart rate. Participants will receive 4 doses of soticlestat in tablets and will complete some assessment which include to record activity of the heart and collection of blood samples. Then, the clinic will contact the participants 14 days after their final dose of soticlestat to check if they have any health problems.

NCT ID: NCT05116969 Withdrawn - Healthy Volunteer Clinical Trials

A Phase 1 Study of PTX-35 in Healthy Volunteers

Start date: November 24, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1, Single Dose-Escalation and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous PTX-35 Adminsitration in Healthy Volunteers

NCT ID: NCT05100927 Withdrawn - Healthy Volunteer Clinical Trials

3D Free-Breathing Multi-echo Acquisition for Whole-body Water/Fat Separation

Start date: January 22, 2022
Phase:
Study type: Observational

The purpose of this study is to help researchers develop MRI imaging techniques that can provide better information for using MRI to treat cancer. MRI is a non-invasive technique that uses magnetic fields and radio waves to create images of the inside of the body. The investigators of this study are developing an MRI imaging technique that will help with treatment planning for cancer patients. Specifically, the method investigating will help to calculate how the dose the patient needs to treat his/her/their cancer is distributed. This information is required for prescribing the dose to the patient for their cancer treatment.

NCT ID: NCT04964050 Withdrawn - Healthy Volunteers Clinical Trials

A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions

Start date: April 21, 2022
Phase: Phase 1
Study type: Interventional

This is a bioequivalence study to compare Capozide (test product [T]) to ACE-Hemmer-ratiopharm (reference product[R]) produced by Ratiopharm GmbH Germany in healthy adult participants under fasting conditions. ACE-Hemmer-ratiopharm®is the registered trademark of Ratiopharm GmbH Germany.

NCT ID: NCT04878315 Withdrawn - Healthy Volunteers Clinical Trials

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Start date: February 13, 2022
Phase: Phase 1
Study type: Interventional

This is a bioequivalence study to compare Capoten (test product [T]) versus captopril (reference product [R]) produced by Mylan Pharmaceuticals Spain, in healthy adult participants under fasting condition. Capoten is the registered trademark of SmithKline Beecham Egypt.

NCT ID: NCT04840927 Withdrawn - Healthy Volunteers Clinical Trials

A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

Start date: April 9, 2021
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the pharmacokinetic (PK) profile of E7386 following oral administration of E7386 enteric coated TR prototype tablet formulations (TR1, TR2 and optional TR3) and to evaluate the relative bioavailability of E7386 TR tablets compared to E7386 IR reference tablet.

NCT ID: NCT04831502 Withdrawn - Healthy Volunteers Clinical Trials

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Start date: April 2, 2021
Phase: Phase 1
Study type: Interventional

The aim of this study is to understand how TAK-906 tablets and capsules are processed by the body in healthy adults under fasting conditions and also how TAK-906 tablets are processed by the body when taken with a high fat high calorie breakfast compared to fasting. This study will require participants to stay at the clinical research unit for about 3 weeks to be monitored after receiving TAK-906.